The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol

被引：0
|
作者：
Kapitza, Christoph
Flint, Anne
Hindsberger, Charlotte
Zdravkovic, Milan
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A593 / A593
页数：1
相关论文
共 50 条
  • [21] The Relationship between Pharmacokinetics of the Once-Daily Human GLP-1 Analog Liraglutide and Pharmacodynamic Effects on Glycemia, Gastric Emptying and Energy Intake
    Flint, Anne
    Hindsberger, Charlotte
    DIABETES, 2010, 59 : A420 - A420
  • [22] A meta-analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure
    Fonseca, V.
    Falahati, A.
    Zychma, M.
    Madsbad, S.
    Plutzky, J.
    DIABETOLOGIA, 2009, 52 : S299 - S299
  • [23] Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride
    Bode, B. W.
    Hale, P. M.
    Hammer, M.
    Testa, M. A.
    Garber, A.
    DIABETOLOGIA, 2008, 51 : S357 - S358
  • [24] The once-daily human GLP-1 analogue liraglutide increases the beta cell mass in normoglycaemic mice by directly accelerating cell differentiation and proliferation
    Shimoda, M.
    DIABETOLOGIA, 2009, 52 : S34 - S35
  • [25] Pharmacokinetic modelling of the once-daily human GLP-1 analogue liragiutide in healthy volunteers and comparison to exenatide
    Jonker, Daniel
    Toft, Anders D.
    Kristensen, Peter
    Knudsen, Lotte
    Watson, Estelle
    DIABETES, 2007, 56 : A160 - A160
  • [26] Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass
    Meier, J. J.
    Vilsboll, T.
    Donsmark, M.
    Hartvig, H.
    Nauck, M. A.
    DIABETOLOGIA, 2011, 54 : S322 - S322
  • [27] Liraglutide, the once-daily human GLP-1 analogue, has a protracted profile based on both delayed absoprtion and a long plasma half-life
    Knudsen, L. Bjerre
    Nielsen, P. F.
    Steensgaard, D. B.
    Bloch, P.
    Lau, J.
    Agersoe, H.
    DIABETOLOGIA, 2009, 52 : S305 - S306
  • [28] Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
    Horowitz, M.
    Vilsboll, T.
    Zdravkovic, M.
    Hammer, M.
    Madsbad, S.
    DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 593 - U4
  • [29] Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase
    Bjornsdottir, I.
    Olsen, A.
    Larsen, U.
    Helleberg, H.
    Vanggaard, J.
    Oosterhuis, B.
    van Lier, J.
    Zdravkovic, M.
    Malm-Erjefalt, M.
    DIABETOLOGIA, 2008, 51 : S356 - S356
  • [30] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 843 - 854
12345